Continuous glucose monitors like Dexcom's Stelo and Abbott's Lingo are small, wearable devices that track blood glucose levels in real-time in non-diabetics.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Continuous glucose monitoring (CGM) devices provide real-time blood sugar readings 24 hours a day, allowing people with type 1 or type 2 diabetes to closely track blood glucose levels and trends. Most ...

Medical device company DexCom (NASDAQ:DXCM) reported Q4 CY2024 results , with sales up 7.6% year on year to $1.11 billion.

DexCom (NASDAQ:DXCM), known for its continuous glucose monitoring (CGM ... Conversely, the Non-GAAP operating income dropped 13.7% to $209.5 million, and the Non-GAAP EPS of $0.45 indicated ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

Operating income (non-GAAP) decreased to $209.5 million from $242.7 million ... earnings per share falling short. DexCom specializes in continuous glucose monitoring systems, primarily focusing ...

Just a few weeks after Dexcom’s Stelo became the first over-the-counter continuous glucose monitor (CGM ... domestic CGM market in the US to reach $7.8 billion in 2025 and more than $10 billion ...

Today, Benzinga's options scanner identified 8 options transactions for DexCom. This is an unusual occurrence. The sentiment ...